Plain-English translation of NCT05952557 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , a new type of hormone-blocking medication taken by mouth, works better than standard hormone therapy (such as aromatase inhibitors or ) to prevent breast cancer from coming back in patients with early-stage, hormone-responsive breast cancer. The study involves about 5,500 patients and will track outcomes for 10 years. You would take the medication daily for up to 7 years.
Current hormone therapies have helped many patients, but some people still experience cancer recurrence. This medication represents a newer approach to blocking estrogen in the body, and researchers want to know whether it offers better protection against the cancer returning compared to standard treatments.
You would be randomly assigned to either take the new medication () or standard hormone therapy, both taken as daily pills for up to 7 years. You would have regular clinic visits to check on your health, have blood tests, and report any side effects. You may also optionally receive an additional cancer medication () in either group if your doctor recommends it. Researchers will continue to follow you for 10 years from the time the last patient enrolled to see how well the treatment works and whether the cancer returns.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
United States